Information Provided By: 
Fly News Breaks for April 5, 2017
NLNK
Apr 5, 2017 | 08:12 EDT
SunTrust analyst Peter Lawson says that interim data on NewLink's Indoximod is "encouraging." The analyst says that "Indoximod + IO has comparable efficacy to approved IO combos, but is more tolerable," and he expects the data to improve going forward. He adds that the drug's "durability is encouraging." He reiterates a $30 price target and a Buy rating on the shares. ,
News For NLNK From the Last 2 Days
There are no results for your query NLNK
